Large Scale Biology Adds Professor David Baulcombe to its Scientific Advisory Board.Business Editors/Health & Medical Writers VACAVILLE, Calif.--(BW HealthWire)--June 26, 2001 Large Scale Biology Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :LSBC LSBC Law Society of British Columbia LSBC Large Scale Biology Corporation LSBC Lone Star Bulldog Club LSBC Lasalle & Bureau County Railroad Company LSBC Lifesaver for Babies and Children (St John Ambulance, UK) LSBC Lone Star Bit Company ) announced today that Professor David Baulcombe of the Sainsbury Laboratory This article or section needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. , Norwich, England, has signed a multi-year consulting agreement and has joined LSBC's Scientific Advisory Board. The arrangement also provides for an initial three-year sponsored research program in Professor Baulcombe's lab to further the development of his pioneering work in next generation viral-derived gene silencing and overexpression technologies. "Professor Baulcombe is recognized as a world leader in characterizing the mechanisms of post-transcriptional gene silencing (PTGS PTGS Post-Transcriptional Gene Silencing ), currently known as RNA interference RNA interference n. A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes. (RNAi), and has helped demonstrate the utility of this phenomenon to determine gene function in higher organisms. His work in higher plants, that led to our understanding of RNAi, has already given rise to numerous practical applications in diverse organisms from higher plants to fruit flies, to nematodes, and ultimately to mammalian species," said Dr. Laurence K. Grill, Senior Vice President of R&D and a co-founder of LSBC. "Under the recently announced, broad exclusive license from Plant Bioscience, Ltd., covering certain viral-derived gene silencing and overexpression technologies developed by Dr. Baulcombe and others, we intend to commercialize innovative uses of this technology which also may be used synergistically syn·er·gis·tic adj. 1. Of or relating to synergy: a synergistic effect. 2. Producing or capable of producing synergy: synergistic drugs. 3. with LSBC's GENEWARE(R) plant viral vectors," said Dr. Grill. "I am excited to join forces with an outstanding group of scientists and respected colleagues at LSBC. The Company has pioneered the commercial development of viral-based manufacturing and high-throughput functional genomics Noun 1. functional genomics - the branch of genomics that determines the biological function of the genes and their products genomics - the branch of genetics that studies organisms in terms of their genomes (their full DNA sequences) in plants. LSBC is a natural choice of partner to help advance fundamental discoveries in my laboratory and to help realize the potential application of our work," said Professor Baulcombe. About the Sainsbury Laboratory The Sainsbury Laboratory has a worldwide reputation for research on molecular plant pathology Molecular Plant Pathology is a journal published in association with the British Society for Plant Pathology. It was first published in January 2000. It has an impact factor of 3.3 ranking it 15th in the list of all plant science journals. . The major aim of the Laboratory is to investigate the fundamental processes involved in the interactions of plants and their pathogens. The Laboratory is located at the John Innes Centre The John Innes Centre (JIC) in Norwich, Norfolk, England is Europe's premier independent centre for research and training in plant and microbial science. It was named after John Innes, a merchant and philanthropist who bequeathed his home at Merton Park and funds for the founding , Norwich, UK, which is a world-leading research center in plant and microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. science. For more information on the Sainsbury Laboratory and the John Innes Centre, please access the website www.jic.bbsrc.ac.uk. About Large Scale Biology Corporation Large Scale Biology uses its proteomics, functional genomics and biomanufacturing technologies to develop and manufacture personalized drugs, vaccines and diagnostics for rapid identification and effective treatment of disease. Corporate offices and the Genomics and Antigenics divisions are headquartered in Vacaville, California; the Company's Proteomics subsidiary is located in Germantown, Maryland; and the Company's bioprocessing and manufacturing facilities are located in Owensboro, Kentucky. For more information about Large Scale Biology Corporation, visit the Company's website at www.lsbc.com. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such forward-looking statements are based on our current plans, expectations, estimates, and projections and management's beliefs about our future performance. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates" or variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties that are difficult to predict and which may cause our actual results and performance to differ materially from those expressed or forecasted in any such forward-looking statements. For a further list and description of such risks and uncertainties see the reports filed by Large Scale Biology Corporation with the Securities Exchange Commission. Unless required by law, Large Scale Biology Corporation undertakes no obligation to update publicly any forward-looking statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion